Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6435-6439

  Zhou, Jing ^a   Wei, Yue Hua ^a   Liao, Mei Yan ^a   Xiong, Yan ^a   Li, Jie Lan ^a   Cai, Hong Bing ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Electrospray tandem MS; Maldi TOF MS; Ovarian cancer; Proteomics

Indexed keywords

AARF DOMAIN CONTAINING KINASE 4, HUMAN; ACTIN DEPOLYMERIZING FACTOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKERATIN 1; CYTOKERATIN 9; PROTEIN KINASE;

ARTICLE; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METHODOLOGY; OVARY TUMOR; PROTEOMICS; TUMOR CELL LINE;

ACTIN DEPOLYMERIZING FACTORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KERATIN-1; KERATIN-9; OVARIAN NEOPLASMS; PROTEIN KINASES; PROTEOMICS;

EID: 84877045238     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6435     Document Type: Article

References (27)

1. Aebi S, Kurdi-Haidar B, Gordon R, et al (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res, 56, 3087-90.
2. Andrea U, Julia P and Sergio B (2005). A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics, 5, 796-804.
3. Canman CE, Radany EH, Parsels LA, et al (1994). Davis MA, Lawrence TS and Maybaum J: Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichi a coli deoxyuridinetriphosphatase. Cancer Res, 54, 2296-8.
4. Cecconi D, Donadelli M, Scarpa A, et al (2005). Proteomic analysis pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J Proteome Res, 4, 1909-16.
5. Chua BT, Volbracht C, Tan KO, et al (2003). Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat Cell Biol, 5, 1083-9.
6. DesMarais V, Ghosh M, Eddy R, et al (2005). Cofilin takes the lead. J Cell Sci, 118, 19-26.
7. Hamada S, Kamada M, Furumoto H, et al (1994). Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol, 52, 313-9.
8. Jemal A, Siegel R, Ward E et al (2009). Cancer statistics. CA Cancer J Clin, 59, 225-49.
9. Kartalou M and Essigmann JM (2001). Mechanisms of resistance to cisplatin. Mutat Res, 478, 23-43.
10. Kim SW, Kim S, Nam EJ, et al (2011). Comparative Proteomic Analysis of Advanced Serous Epithelial Ovarian Carcinoma: Possible Predictors of Chemoresistant disease. OMICS, 15, 281-92.
11. Liu CC, Lu TC, Li HH, et al (2010). Phosphoproteomic identifi- cation and phylogenetic analysis of ribosomal P-proteins in Populus dormant terminal buds. Planta, 231, 571-81.
12. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
13. Marth C, Widschwendter M, KaernJ, et al (1997). Cisplatin resistance is associated with reduced interfer on-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Cance, 76, 1328-32.
14. Ozols RF and Young RC (1985). High-dose cisplatin therapy in ovarian cancer. Semin Oncol, 12, 21-30.
15. Rudin CM, Yang Z, Schumaker LM, et al (2003). Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res, 63, 312-8.
16. Sasaki H, Sheng Y, Kotsuji F and Tsang BK (2000). Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res, 60, 5659-66.
17. Veneroni S, Zaffaroni N, Daidone MG, et al (1994). Expression of P-glycoprote- in and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer, 30A, 1002-7.
18. Wang WG, Goswami S, Lapidus K, et al (2004). Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res, 64: 8585-94.
19. Wang W, Mouneimne G, Sidani M, et al (2006). The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol, 173, 395-404.
20. Williams J, Lucas PC, Griffith KA, et al (2005). Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol, 96, 287-95.
21. Wong CS, Wong VW, Chan CM, et al (2008). Identification of 5-fluorouracil response proteins in colorectal cacinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Pep, 20, 89-98.
22. Yuan ZQ, Feldman RI, Sussman GE, et al (2003). AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1-Implication of AKT2 in chemoresistance. J Biol Chem, 278, 23432-40.
23. Yuan Z, Wang F, Zhao ZW, et al (2011). BIM-Mediated AKT Phosphory- lation Is a Key Modulator of Arsenic Trioxide-Induced Apoptosis in Cisplatin-Sensitive and-Resistant Ovarian Cancer Cells. PLOS ONE, 6, e20586.
24. Yang JW, Rodrigo R, Felipo V and Lubec GJ (2005), Proteome analysis of primary neurons and astrocytes from rat cerebellum. J Proteome Res, 4, 768-88.
25. Yan XD, Pan LY, Yuan Y, et al (2007). Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res, 6, 772-80.
26. Zhou YZ, Chen HZ and Yang QY (1996). Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance. Natl Med J China, 76, 680-3.
27. Zhu BB, Fukada K, Zhu HN and Kyprianou N (2006). Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res, 66, 8640-7.